Non-Invasive Brush Biopsy Test Detects Oral Squamous Cell Carcinoma with 95.5% Accuracy in Under One Hour
Key Insights
A novel non-invasive oral brush biopsy test (qMIDSV3) demonstrated 95.7% sensitivity and 95.1% specificity for detecting oral squamous cell carcinoma (search) in a large diagnostic case-control study of 545 patients.
The test can deliver results within one hour and could spare over 90% of patients with low-risk oral potentially malignant disorders from unnecessary invasive scalpel biopsies.
Researchers were surprised that the brush swab test performed comparably to a microbiopsy, suggesting the four-gene molecular signature is robust enough for superficial cell sampling.
A rapid, non-invasive brush biopsy test adapted from a molecular assay can distinguish oral squamous cell carcinoma (search) (OSCC) from other oral disorders with high accuracy, according to results from a large diagnostic case-control study published in Biomarker Research. The test, known as qMIDSV3, achieved an overall accuracy of 95.5%, offering a potential paradigm shift in how clinicians triage patients with suspicious oral lesions.
The study, led by researchers at Queen Mary University of London in collaboration with institutions in India, is the largest of its kind, involving over 1,000 samples from 545 patients.
"Oral cancer survival is directly linked to how early it is found, yet our current diagnostic pathway is blunt—most patients with a suspicious lesion end up having an invasive biopsy even when the overwhelming likelihood is that it is benign. This test changes that," said lead researcher Muy-Teck Teh, BSc (Hons), PhD, FHEA, Professor of Molecular Oral Oncology at Queen Mary University of London. "It gives clinicians a rapid, accurate, and non-invasive way to triage patients, and crucially, it can be repeated. That means we can now monitor patients with persistent premalignant lesions regularly and systematically—and pick up cancers much earlier than we would have been able to before."
The Diagnostic Challenge in Oral Cancer
Oral cancer represents a growing global health burden. According to Global Burden of Disease data, lip and oral cancer is among the world's most rapidly increasing causes of early death. Over 10,000 people in the UK were diagnosed with oral cancer last year, and 3,637 people lost their lives. Worldwide, the disease affects 650,000 individuals annually.
More than half—53%—of all mouth cancers are diagnosed at stage IV, when the cancer is at its most advanced. Risk factors include tobacco use, alcohol consumption, HPV infection, and sun damage.
The current diagnostic pathway presents significant challenges. A 10-year UK audit reported a 450% rise in two-week wait referrals alongside a 50% drop in cancer detection rates. Subsequent audits showed that 92.5% to 99.5% of referred patients were cancer-free, with most (96%–98%) remaining cancer-free at five-year follow-up. These findings highlight substantial over-referral and inefficiency in current pathways.
Scalpel biopsies, the current standard for definitive diagnosis, can be extremely painful—particularly on the tongue, the most common cancer site—and may lead to infection or damage to underlying tooth and bone structures. This discourages both patients and clinicians from pursuing timely, repeated assessments.
Study Design and Methodology
The prospective diagnostic case-control study used 1,090 oral brush biopsies paired with contralateral nonlesion mucosa from 545 patients. Quantitative polymerase chain reaction (qPCR) testing quantified mRNA levels of four genes—INHBA (search), S100A16 (search), YAP1 (search), and POLR2A (search)—from each brush biopsy. Researchers then applied a qMIDS algorithm to compute a malignancy index, stratifying cancer risk for each patient.
The study sought to determine whether a previously validated microbiopsy-based multigene assay (qMIDSV2) could be adapted into a rapid, non-invasive brush biopsy test for accurate OSCC detection.
Key Findings
The adapted qMIDSV3 brush biopsy test differentiated oral squamous cell carcinoma (search) from oral leukoplakia (search) and oral lichen planus (search) with an area under the curve (AUC) of 0.975, a sensitivity of 95.7%, a specificity of 95.1%, and an overall accuracy of 95.5%. The false-positive rate was 4.9% and the false-negative rate was 4.3%.
INHBA (search) and S100A16 (search) were identified as key biomarkers for oral squamous cell carcinoma (search) in brush biopsies.
"We were genuinely astonished by the fact that the brush swab test performance is comparable to a microbiopsy," Dr. Teh said. "It suggests that the biological signal captured by these four genes is sufficiently strong and consistent that it can be detected even from the superficial exfoliated cells collected by a brush biopsy. The clinical implications are significant: patients no longer need even a minimally invasive procedure to benefit from molecularly guided triage."
Clinical Implications and Future Directions
The study authors concluded that qMIDSV3 could serve as a rapid case-finding or triage test, potentially sparing most patients with low-risk oral potentially malignant disorders (OPMDs) from unnecessary invasive tissue biopsies. Implementing a rapid, non-invasive triage test such as qMIDSV3 could reduce unnecessary referrals for over 90% of cancer-free patients and lessen the clinical and financial burden of managing OPMDs and OSCC.
Beyond initial diagnosis, the test offers a critical capability for long-term surveillance. Because it is non-invasive and repeatable, qMIDSV3 supports serial testing to monitor patients with persistent OPMDs—conditions known to carry a risk of malignant transformation that is difficult to predict clinically. Serial testing could significantly improve the chances of detecting early-stage cancers in this high-risk group.
The cross-continental validation of the predecessor qMIDSV2 assay across more than 530 samples from the UK, India, and China established the robustness of the underlying multigene signature across diverse patient populations and clinical settings.
Queen Mary University of London is actively seeking a commercial partner to help develop the test for clinical use. With the right partner, the inexpensive test could be in use within two years.